Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preethi Krishnan

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal of Gastroenterology|September 27, 2017
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosisKazuaki Chayama, Fumitaka Suzuki, Yoshiyasu Karino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Critical Care Explorations|December 10, 2025
Continuous Physiologic Markers of Heart Rate Variability Derived From Bedside Electrocardiogram Precede Onset of Acute Respiratory Distress Syndrome: A Physiologic Modeling StudyCurtis E Marshall, Haoming Shi, Ayman Ali, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceFarooq Syed, Olivia Ballew, Chih-Chun Lee, et al.
Bioorganic & Medicinal Chemistry|November 20, 2019
Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virusA Chris Krueger, Hui-Ju Chen, John T Randolph, et al.
Nature Chemical Biology|November 1, 2011
Identifying polyglutamine protein species in situ that best predict neurodegenerationJason Miller, Montserrat Arrasate, Elizabeth Brooks, et al.
Ebiomedicine|May 7, 2025
Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceFarooq Syed, Olivia Ballew, Chih-Chun Lee, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal of Gastroenterology|September 27, 2017
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosisKazuaki Chayama, Fumitaka Suzuki, Yoshiyasu Karino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Critical Care Explorations|December 10, 2025
Continuous Physiologic Markers of Heart Rate Variability Derived From Bedside Electrocardiogram Precede Onset of Acute Respiratory Distress Syndrome: A Physiologic Modeling StudyCurtis E Marshall, Haoming Shi, Ayman Ali, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceFarooq Syed, Olivia Ballew, Chih-Chun Lee, et al.
Bioorganic & Medicinal Chemistry|November 20, 2019
Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virusA Chris Krueger, Hui-Ju Chen, John T Randolph, et al.
Nature Chemical Biology|November 1, 2011
Identifying polyglutamine protein species in situ that best predict neurodegenerationJason Miller, Montserrat Arrasate, Elizabeth Brooks, et al.
Ebiomedicine|May 7, 2025
Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceFarooq Syed, Olivia Ballew, Chih-Chun Lee, et al.
Pageof 9